Krishna Institute Of Medical Sciences Limited

PE of 158.3 is extremely high; the market prices in substantial future earnings growth—verify that the company can deliver high EPS CAGR, as a miss would trigger sharp revaluation.

D/E of 1.44 combined with ROE of 11% means modest returns on borrowed capital; assess debt sustainability if operating margins fall from their 28–29% highs.

Operating margins swing from 19.22% to 28.9% across quarters; verify whether this reflects seasonal patterns or operational inconsistency.

Promoter stake of 32.5% is moderate compared to peer hospital chains; verify management's long-term commitment to shareholder value creation.

Q4 FY2026 and Q2 FY2026 achieved OPM of 28.61% and 26.09% respectively; sustaining these margin levels while growing absolute revenue from the ₹430–₹484 Cr quarterly range would expand per-share earnings.

Latest EPS of 1.66 falls within the 1.04–1.81 recent range; with PE of 158.3, investors expect sustained high EPS growth—verify whether bed-capacity additions, pricing trends, and volume drivers support this.

D/E of 1.44 provides earnings leverage; modest ROE improvement from 11% through volume or margin expansion would compound into material per-share returns—verify pathway to higher ROE.